Paul A van der Zwaag
Overview
Explore the profile of Paul A van der Zwaag including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1088
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berends M, Tingen H, Bijzet J, Lemmink H, Muntinghe F, Houwerzijl E, et al.
Amyloid
. 2025 Mar;
:1-4.
PMID: 40065656
No abstract available.
2.
Tingen H, Groothof D, Tubben A, Bijzet J, Houwerzijl E, Muntinghe F, et al.
Eur J Nucl Med Mol Imaging
. 2024 Aug;
52(1):88-97.
PMID: 39115713
Purpose: Bone scintigraphy is key to non-invasively diagnosing wild-type transthyretin (ATTRwt) amyloidosis, and is mainly used to assess cardiac radiotracer uptake. However, extracardiac radiotracer uptake is also observed. We investigated...
3.
Nicastro M, Vermeer A, Postema P, Tadros R, Bowling F, Aegisdottir H, et al.
medRxiv
. 2024 Jul;
PMID: 39006410
Graphical Abstract:
4.
van der Heide M, Verstraelen T, van Lint F, Bosman L, de Brouwer R, Proost V, et al.
Europace
. 2024 Apr;
26(4).
PMID: 38558121
Aims: Recently, a genetic variant-specific prediction model for phospholamban (PLN) p.(Arg14del)-positive individuals was developed to predict individual major ventricular arrhythmia (VA) risk to support decision-making for primary prevention implantable cardioverter...
5.
Berends M, Brunger A, Bijzet J, Kroesen B, Drost G, Lange F, et al.
Amyloid
. 2024 Mar;
31(2):132-141.
PMID: 38477065
Objective: To evaluate serum neurofilament light chain (sNfL) as biomarker of disease onset, progression and treatment effect in hereditary transthyretin (ATTRv) amyloidosis patients and variant (v) carriers. Methods: sNfL levels...
6.
van de Leur R, de Brouwer R, Bleijendaal H, Verstraelen T, Mahmoud B, Perez-Matos A, et al.
Heart Rhythm
. 2024 Feb;
21(7):1102-1112.
PMID: 38403235
Background: Phospholamban (PLN) p.(Arg14del) variant carriers are at risk for development of malignant ventricular arrhythmia (MVA). Accurate risk stratification allows timely implantation of intracardiac defibrillators and is currently performed with...
7.
Tingen H, Berends M, Tubben A, Bijzet J, Houwerzijl E, Muntinghe F, et al.
J Clin Med
. 2024 Feb;
13(3).
PMID: 38337504
(1) Background: Individuals carrying a pathogenic transthyretin gene variant () are at high risk for developing hereditary transthyretin (ATTRv) amyloidosis and are routinely screened for the development of cardiomyopathy (ATTRv-CM)....
8.
Schoonvelde S, Ruijmbeek C, Hirsch A, van Slegtenhorst M, Wessels M, von der Thusen J, et al.
Heart Rhythm
. 2023 Aug;
20(11):1512-1521.
PMID: 37562486
Background: Dilated cardiomyopathy (DCM) can be caused by truncating variants in the filamin C gene (FLNC). A new pathogenic FLNC variant, c.6864_6867dup, p.(Val2290Argfs∗23), was recently identified in Dutch patients with...
9.
van Lint F, Hassanzada F, Verstraelen T, Wang W, Bosman L, van der Zwaag P, et al.
Neth Heart J
. 2023 Jul;
31(7-8):291-299.
PMID: 37474840
Background: Endurance and frequent exercise are associated with earlier onset of arrhythmogenic right ventricular cardiomyopathy (ARVC) and ventricular arrhythmias (VA) in desmosomal gene variant carriers. Individuals with the pathogenic c.40_42del;...
10.
de Brouwer R, Te Rijdt W, Hoorntje E, Amin A, Asselbergs F, Cox M, et al.
Eur Heart J
. 2023 May;
44(40):4284-4287.
PMID: 37210081
No abstract available.